Cargando…
Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
BACKGROUND: Prior to the introduction of tamoxifen, high dose estradiol was used to treat breast cancer patients with similar efficacy as tamoxifen, albeit with some undesirable side effects. There is renewed interest to utilize estradiol to treat endocrine resistant breast cancers, especially since...
Autores principales: | Perez White, Bethany, Molloy, Mary Ellen, Zhao, Huiping, Zhang, Yiyun, Tonetti, Debra A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661391/ https://www.ncbi.nlm.nih.gov/pubmed/23634843 http://dx.doi.org/10.1186/1476-4598-12-34 |
Ejemplares similares
-
Retraction Note to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: White, Bethany Perez, et al.
Publicado: (2017) -
PKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients
por: Tonetti, Debra A., et al.
Publicado: (2012) -
Automated Quantification of Extranuclear ERα Using Phosphor-Integrated Dots for Predicting Endocrine Therapy Resistance in HR(+)/HER2(−) Breast Cancer
por: Guo, Zhaorong, et al.
Publicado: (2019) -
PKCα and PKCδ: Friends and Rivals
por: Black, Jennifer D., et al.
Publicado: (2022) -
Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin
por: Pham, Thao N. D., et al.
Publicado: (2017)